Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Corrigendum to "A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles" [Virology 507 (2017) 242-256].

Meador LR, Kessans SA, Kilbourne J, Kibler KV, Pantaleo G, Esteban M, Blattman JN, Jacobs BL, Mor TS.

Virology. 2019 Aug;534. pii: S0042-6822(19)30139-4. doi: 10.1016/j.virol.2019.05.018. Epub 2019 Jun 6. No abstract available.

PMID:
31178060
2.

Sequence-specific detection of different strains of LCMV in a single sample using tentacle probes.

Franco LS, Holechek SA, Caplan MR, Blattman JN.

Virol J. 2017 Oct 13;14(1):197. doi: 10.1186/s12985-017-0863-9.

3.

Reproduction Alters Hydration State but Does Not Impact the Positive Effects of Dehydration on Innate Immune Function in Children's Pythons (Antaresia childreni).

Brusch GA 4th, Billy G, Blattman JN, DeNardo DF.

Physiol Biochem Zool. 2017 Nov/Dec;90(6):646-654. doi: 10.1086/694834.

PMID:
28991506
4.

A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles.

Meador LR, Kessans SA, Kilbourne J, Kibler KV, Pantaleo G, Roderiguez ME, Blattman JN, Jacobs BL, Mor TS.

Virology. 2017 Jul;507:242-256. doi: 10.1016/j.virol.2017.04.008. Epub 2017 Apr 28. Erratum in: Virology. 2019 Aug;534:.

5.

Retinaldehyde dehydrogenase 2 as a molecular adjuvant for enhancement of mucosal immunity during DNA vaccination.

Holechek SA, McAfee MS, Nieves LM, Guzman VP, Manhas K, Fouts T, Bagley K, Blattman JN.

Vaccine. 2016 Nov 4;34(46):5629-5635. doi: 10.1016/j.vaccine.2016.09.013. Epub 2016 Sep 23.

6.

Progress and opportunities for immune therapeutics in osteosarcoma.

Lettieri CK, Appel N, Labban N, Lussier DM, Blattman JN, Hingorani P.

Immunotherapy. 2016 Oct;8(10):1233-44. doi: 10.2217/imt-2016-0048. Review.

PMID:
27605071
7.

Enhanced immunity in a mouse model of malignant glioma is mediated by a therapeutic ketogenic diet.

Lussier DM, Woolf EC, Johnson JL, Brooks KS, Blattman JN, Scheck AC.

BMC Cancer. 2016 May 13;16:310. doi: 10.1186/s12885-016-2337-7.

8.

Interaction between unrelated viruses during in vivo co-infection to limit pathology and immunity.

McAfee MS, Huynh TP, Johnson JL, Jacobs BL, Blattman JN.

Virology. 2015 Oct;484:153-62. doi: 10.1016/j.virol.2015.05.021. Epub 2015 Jun 20.

9.

Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma.

Lussier DM, Johnson JL, Hingorani P, Blattman JN.

J Immunother Cancer. 2015 May 19;3:21. doi: 10.1186/s40425-015-0067-z. eCollection 2015.

10.

TCR contact residue hydrophobicity is a hallmark of immunogenic CD8+ T cell epitopes.

Chowell D, Krishna S, Becker PD, Cocita C, Shu J, Tan X, Greenberg PD, Klavinskis LS, Blattman JN, Anderson KS.

Proc Natl Acad Sci U S A. 2015 Apr 7;112(14):E1754-62. doi: 10.1073/pnas.1500973112. Epub 2015 Mar 23.

11.

Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions.

Lussier DM, O'Neill L, Nieves LM, McAfee MS, Holechek SA, Collins AW, Dickman P, Jacobsen J, Hingorani P, Blattman JN.

J Immunother. 2015 Apr;38(3):96-106. doi: 10.1097/CJI.0000000000000065.

12.

Nuclear factor kappa B is required for the production of infectious human herpesvirus 8 virions.

Blattman NN, Lagunoff M, Blattman JN, Corey L.

Front Microbiol. 2014 Apr 4;5:129. doi: 10.3389/fmicb.2014.00129. eCollection 2014.

13.

Estimating the diversity, completeness, and cross-reactivity of the T cell repertoire.

Zarnitsyna VI, Evavold BD, Schoettle LN, Blattman JN, Antia R.

Front Immunol. 2013 Dec 26;4:485. doi: 10.3389/fimmu.2013.00485. Review.

14.

Engineering recombinant reoviruses with tandem repeats and a tetravirus 2A-like element for exogenous polypeptide expression.

Demidenko AA, Blattman JN, Blattman NN, Greenberg PD, Nibert ML.

Proc Natl Acad Sci U S A. 2013 May 14;110(20):E1867-76. doi: 10.1073/pnas.1220107110. Epub 2013 Apr 29.

15.

Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens.

Wegmann F, Gartlan KH, Harandi AM, Brinckmann SA, Coccia M, Hillson WR, Kok WL, Cole S, Ho LP, Lambe T, Puthia M, Svanborg C, Scherer EM, Krashias G, Williams A, Blattman JN, Greenberg PD, Flavell RA, Moghaddam AE, Sheppard NC, Sattentau QJ.

Nat Biotechnol. 2012 Sep;30(9):883-8.

16.

Abrogation of SRC homology region 2 domain-containing phosphatase 1 in tumor-specific T cells improves efficacy of adoptive immunotherapy by enhancing the effector function and accumulation of short-lived effector T cells in vivo.

Stromnes IM, Fowler C, Casamina CC, Georgopolos CM, McAfee MS, Schmitt TM, Tan X, Kim TD, Choi I, Blattman JN, Greenberg PD.

J Immunol. 2012 Aug 15;189(4):1812-25. doi: 10.4049/jimmunol.1200552. Epub 2012 Jul 13.

17.

Combating chronic T-cell exhaustion.

McAfee MS, Blattman JN.

Immunotherapy. 2012 Jun;4(6):557-60. doi: 10.2217/imt.12.46. No abstract available.

18.

Rescued tolerant CD8 T cells are preprogrammed to reestablish the tolerant state.

Schietinger A, Delrow JJ, Basom RS, Blattman JN, Greenberg PD.

Science. 2012 Feb 10;335(6069):723-7. doi: 10.1126/science.1214277. Epub 2012 Jan 19.

19.

Retinoic acid as a vaccine adjuvant enhances CD8+ T cell response and mucosal protection from viral challenge.

Tan X, Sande JL, Pufnock JS, Blattman JN, Greenberg PD.

J Virol. 2011 Aug;85(16):8316-27. doi: 10.1128/JVI.00781-11. Epub 2011 Jun 8.

20.

Vaccination alters the balance between protective immunity, exhaustion, escape, and death in chronic infections.

Johnson PL, Kochin BF, McAfee MS, Stromnes IM, Regoes RR, Ahmed R, Blattman JN, Antia R.

J Virol. 2011 Jun;85(11):5565-70. doi: 10.1128/JVI.00166-11. Epub 2011 Mar 16.

21.

Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectors.

Rhee EG, Blattman JN, Kasturi SP, Kelley RP, Kaufman DR, Lynch DM, La Porte A, Simmons NL, Clark SL, Pulendran B, Greenberg PD, Barouch DH.

J Virol. 2011 Jan;85(1):315-23. doi: 10.1128/JVI.01597-10. Epub 2010 Oct 20.

22.

Abrogating Cbl-b in effector CD8(+) T cells improves the efficacy of adoptive therapy of leukemia in mice.

Stromnes IM, Blattman JN, Tan X, Jeevanjee S, Gu H, Greenberg PD.

J Clin Invest. 2010 Oct;120(10):3722-34. doi: 10.1172/JCI41991. Epub 2010 Sep 20.

23.

SHP-1 in T cells limits the production of CD8 effector cells without impacting the formation of long-lived central memory cells.

Fowler CC, Pao LI, Blattman JN, Greenberg PD.

J Immunol. 2010 Sep 15;185(6):3256-67. doi: 10.4049/jimmunol.1001362. Epub 2010 Aug 9.

24.

Impact of epitope escape on PD-1 expression and CD8 T-cell exhaustion during chronic infection.

Blattman JN, Wherry EJ, Ha SJ, van der Most RG, Ahmed R.

J Virol. 2009 May;83(9):4386-94. doi: 10.1128/JVI.02524-08. Epub 2009 Feb 11.

25.

Molecular signature of CD8+ T cell exhaustion during chronic viral infection.

Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, Kalia V, Subramaniam S, Blattman JN, Barber DL, Ahmed R.

Immunity. 2007 Oct;27(4):670-84. Epub 2007 Oct 18. Erratum in: Immunity. 2007 Nov;27(5):824.

26.

Viral antigen and extensive division maintain virus-specific CD8 T cells during chronic infection.

Shin H, Blackburn SD, Blattman JN, Wherry EJ.

J Exp Med. 2007 Apr 16;204(4):941-9. Epub 2007 Apr 9.

27.

PD-1 blockade: rescue from a near-death experience.

Blattman JN, Greenberg PD.

Nat Immunol. 2006 Mar;7(3):227-8. No abstract available.

PMID:
16482167
28.
29.

Antigen-independent memory CD8 T cells do not develop during chronic viral infection.

Wherry EJ, Barber DL, Kaech SM, Blattman JN, Ahmed R.

Proc Natl Acad Sci U S A. 2004 Nov 9;101(45):16004-9. Epub 2004 Oct 25.

30.

Regulation of innate and adaptive immune responses by MAP kinase phosphatase 5.

Zhang Y, Blattman JN, Kennedy NJ, Duong J, Nguyen T, Wang Y, Davis RJ, Greenberg PD, Flavell RA, Dong C.

Nature. 2004 Aug 12;430(7001):793-7.

31.

Cancer immunotherapy: a treatment for the masses.

Blattman JN, Greenberg PD.

Science. 2004 Jul 9;305(5681):200-5. Review.

PMID:
15247469
32.

Changing immunodominance patterns in antiviral CD8 T-cell responses after loss of epitope presentation or chronic antigenic stimulation.

van der Most RG, Murali-Krishna K, Lanier JG, Wherry EJ, Puglielli MT, Blattman JN, Sette A, Ahmed R.

Virology. 2003 Oct 10;315(1):93-102.

33.

Restoration of CD28 expression in CD28- CD8+ memory effector T cells reconstitutes antigen-induced IL-2 production.

Topp MS, Riddell SR, Akatsuka Y, Jensen MC, Blattman JN, Greenberg PD.

J Exp Med. 2003 Sep 15;198(6):947-55. Epub 2003 Sep 8.

34.

Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction.

Ho WY, Blattman JN, Dossett ML, Yee C, Greenberg PD.

Cancer Cell. 2003 May;3(5):431-7. Review.

35.

Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo.

Blattman JN, Grayson JM, Wherry EJ, Kaech SM, Smith KA, Ahmed R.

Nat Med. 2003 May;9(5):540-7. Epub 2003 Apr 14.

PMID:
12692546
36.

Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment.

Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R.

J Virol. 2003 Apr;77(8):4911-27.

37.

Gab3-deficient mice exhibit normal development and hematopoiesis and are immunocompetent.

Seiffert M, Custodio JM, Wolf I, Harkey M, Liu Y, Blattman JN, Greenberg PD, Rohrschneider LR.

Mol Cell Biol. 2003 Apr;23(7):2415-24.

38.

Preferential escape of subdominant CD8+ T cells during negative selection results in an altered antiviral T cell hierarchy.

Slifka MK, Blattman JN, Sourdive DJ, Liu F, Huffman DL, Wolfe T, Hughes A, Oldstone MB, Ahmed R, Von Herrath MG.

J Immunol. 2003 Feb 1;170(3):1231-9.

39.

CD8(+) T cell responses: it's all downhill after their prime.

Blattman JN, Cheng LE, Greenberg PD.

Nat Immunol. 2002 Jul;3(7):601-2. No abstract available.

PMID:
12087413
40.

Estimating the precursor frequency of naive antigen-specific CD8 T cells.

Blattman JN, Antia R, Sourdive DJ, Wang X, Kaech SM, Murali-Krishna K, Altman JD, Ahmed R.

J Exp Med. 2002 Mar 4;195(5):657-64.

41.

Evolution of the T cell repertoire during primary, memory, and recall responses to viral infection.

Blattman JN, Sourdive DJ, Murali-Krishna K, Ahmed R, Altman JD.

J Immunol. 2000 Dec 1;165(11):6081-90.

42.

Viral immune evasion due to persistence of activated T cells without effector function.

Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, Altman JD, Ahmed R.

J Exp Med. 1998 Dec 21;188(12):2205-13.

43.

Therapeutic vaccination against chronic viral infection: the importance of cooperation between CD4+ and CD8+ T cells.

Zajac AJ, Murali-Krishna K, Blattman JN, Ahmed R.

Curr Opin Immunol. 1998 Aug;10(4):444-9. Review.

PMID:
9722921

Supplemental Content

Loading ...
Support Center